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ABSTRACT
Although a viral infection is a major triggering factor of asthma and allergic diseases, asthma 
is suggested to be not a predisposing condition for coronavirus disease 2019 (COVID-19) 
infection. However, patients with severe asthma/allergic disease requiring systemic 
corticosteroids or immunosuppressive agents may be at higher risk of more severe clinical 
course of this infectious disease. For allergic patients who have been followed up at an allergy 
clinic in our region, it is recommended that they (patients with asthma, rhinitis, atopic 
dermatitis or chronic urticaria) continue to receive maintenance therapy and be in a well-
controlled status. Patients who have used biologics (currently available for targeting type 2 
inflammation) and allergen immunotherapy should continue the treatment while minimizing 
hospital and face-to-face visits. It is essential to wear protective equipment for the protection 
of health care workers as well as patients. We report this consensus to support allergists and 
clinical immunologists to make optimal decisions under the urgent situation in Asia.
Keywords: Coronavirus; pandemics; Asia; allergy and immunology; asthma; rhinitis;  
atopic dermatitis; chronic urticaria; management; immunotherapy
INTRODUCTION
The coronavirus disease 2019 (COVID-19) outbreak has started from Wuhan in China in late 
December 2019; the World Health Organization (WHO) named this new coronavirus severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of person-to-person 
transmission was confirmed in January 2020, and the first wave of the pandemic has started 
across the globe, including in Asian countries.1 The case-fatality rate among infected patients 
varies in our region: 5.5% in China, 2.2% in Korea, 2.5% in Japan and 0.1% in Singapore, 
which is lower than in the US and European countries.2 Higher mortality rates (8%–15%) 
were reported in elderly patients and patients with comorbid conditions such as hypertension 
and metabolic diseases.1,3 In addition, an important issue is the spreading of this infection to 
healthcare workers (HCWs). In China, 3.8% of the cases were found in HCWs (14.8% among 




Received: May 14, 2020
Revised: May 27, 2020
Accepted: May 27, 2020
Correspondence to
Hae-Sim Park, MD, PhD
Department of Allergy and Clinical 
Immunology, Ajou University School of 
Medicine, 164 World cup-ro, Yeongtong-gu, 




Copyright © 2020 The Korean Academy of 
Asthma, Allergy and Clinical Immunology • 
The Korean Academy of Pediatric Allergy and 
Respiratory Disease
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 

















Jae-Hyun Lee ,1 Youngsoo Lee ,2 Suh-Young Lee ,3 Hugo Van Bever ,4  
Hongfei Lou ,5,6 Luo Zhang ,5,6,7 Hae-Sim Park  2*
1 Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University 
College of Medicine, Seoul, Korea
2Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
4Department of Pediatrics, National University Hospital (NUH), Singapore
5 Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical 
University, Beijing, China
6Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China
7Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China
Management of Allergic Patients 
During the COVID-19 Pandemic in Asia
Disclosure
There are no financial or other issues that 
might lead to conflict of interest
them were severe or critical) with a mortality of 0.3%; moreover, 63% of the affected HCWs 
were reported in Wuhan.4
The prevalence of allergic diseases, including asthma and allergic rhinitis (AR), is increasing 
in Asian countries, especially in the elderly,5,6 in which viral infections are major triggering 
factors. Although the initial starting point for COVID-19 appears to have been successful in 
controlling epidemics to the appropriate initial response in this region, there is constantly the 
possibility that a new virus subtype outbreak will begin.7,8 Therefore, we report our consensus 
on how to manage allergic patients during this pandemic as well as how to protect HCWs.
To prevent the spread of this viral infection, the specified preventive measures have been 
applied to the general public and HCWs. The WHO recommended basic protective measures, 
including frequent hand washing, maintaining a social distance of 2 m and practicing 
respiratory hygiene for the public.9 During the COVID-19 pandemic, hospital authorities in 
Korea have restricted entrance to the hospital through strict screening of people by checking 
recent travel history, clinical symptoms and body temperature. Furthermore, all the patients 
have been asked to wear a disposable facial mask with careful monitoring of symptoms and 
temperatures during their stay in the hospital. The American Centers for Disease Control and 
Prevention (CDC) recommended appropriate personal protective equipment for healthcare 
providers, including gowns, gloves, N95 respirators and goggles.1,10
THE RISK OF COVID-19 IN PATIENTS WITH ASTHMA AND 
ALLERGIC DISEASES
Although a respiratory viral infection is a major contributing factor to asthma exacerbation 
as well as a triggering factor, information about the influence of SARS-CoV-2 on asthma 
and allergic diseases is limited. It was reported that none of the 140 patients who were 
hospitalized due to confirmed COVID-19 in Wuhan, China had asthma or other allergic 
diseases such as AR, atopic dermatitis (AD) and food allergy.11 Drug hypersensitivity and 
urticaria were found in 11.4% and 1.4% of the patients, respectively, in that study; their 
relationships to COVID-19 remain unclear. Another report from Wuhan observed a markedly 
lower prevalence of asthma (5 asthmatics among 548 patients with confirmed COVID-19, 
0.9%) compared to the prevalence of adult asthma in Wuhan (6.4%).12 In another recent 
study of the 1,099 patients with COVID-19 admitted, no asthmatics were found among 
the study subjects.13 Korean data demonstrated that none of the 22 patients who died of 
COVID-19 were suffering from asthma or other allergic diseases.3 However, the possibility 
of under-diagnosis or under-reporting exists in those studies. Although it has not been 
determined whether allergy or asthma may predispose patients to COVID-19, non-pandemic 
coronavirus infections have aggravated asthma both in adults and children.14-16 Thus, the 
probability of the aggravation of asthma and other allergic diseases by COVID-19 should be 
considered. Furthermore, as pediatric patients with asthma are at higher risk of respiratory 
viral infections, most experts advise extreme caution in such cases.17
Immunosuppressive agents are frequently used to achieve a well-controlled status in patients 
with asthma or severe allergic diseases. Systemic corticosteroid, one of the most widely used 
rescue medications in allergic diseases, is known to increase the risk for systemic infections, 
and so do other immunosuppressive agents such as methotrexate and cyclosporin.18 
Fortunately, the advent of biologic agents, such as anti-immunoglobulin E (IgE), anti-
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interleukin (IL)-5 and anti-IL-4 antibodies, has improved treatment outcomes with reduction 
in medications including systemic corticosteroids. As it is not clear whether biologics 
may increase the susceptibility to serious infections, further studies are needed to draw 
conclusions. Taken together, we should consider the possibility of bidirectional influences 
between COVID-19 and asthma/allergic diseases, which can be influenced by patients' clinical 
characteristics such as age, comorbid illnesses, and profiles of the medications.
PRACTICE OF ALLERGEN IMMUNOETHERAPY
Allergen-specific immunotherapy (AIT), including subcutaneous immunotherapy (SCIT) and 
sublingual immunotherapy (SLIT), is widely applied to patients with asthma or AR in Asia.19-22 
AIT, especially SCIT, requires long-term regular contacts between HCWs and patients (>3 years). 
During the COVID-19 pandemic, home isolation strategy is necessary to control this highly 
contagious disease, and frequent hospital visits may increase the risk of exposure to the virus.
To prevent the risk of infection and to provide safe medical services, the following control 
measures have been suggested to patients undergoing SCIT in each allergy center.23 
Whenever the patients visit the hospital, they should be asked to take strict screening of 
COVID-19 at the entrance and exit. Only patients with a normal temperature are allowed 
to enter the outpatient clinic. They should wear a disposable surgical mask during their 
stay in the hospital. Any confirmed cases of COVID-19 should stop AIT until this infection 
completely resolves and the viral test result becomes negative.23
A good piece of advice is for HCWs, including physicians, nurses and the administrative staff 
contacting with patients, to wear appropriate personal protective equipment such as N94/95 
protective masks and latex gloves in Korea, while additional protective equipment, including 
waterproof medical caps, anti-fog protective goggles and protective face shields, is required 
in allergy centers in Beijing.
Injections for SCIT should be modified after case-by-case assessment. At the up-dose phase, 
discontinuation of SCIT is recommended if regular visits to the allergy center are difficult. 
Re-initiation can be planned until continuous visits are available. In patients who are at the 
maintenance phase of SCIT, the injection protocol can be adjusted later, and the next dose 
can be administered again as recalculated according to the authoritative guidelines. SLIT can 
be continued without interruption.23 Online consultation and medicine delivery services are 
recommended to reduce the need for patients to visit or stay in an allergy center during the 
COVID-19 pandemic.
PHARMACOLOGIC TREATMENT
Asthma (adult and childhood) and AR
It is well known that common coronaviruses are associated with the worsening of asthma 
symptoms.14,15 Recent reports have suggested that asthma does not increase the risk of 
COVID-19 infection or related complications.3,11,13 However, these data have been obtained 
from hospitalized patients with COVID-19; therefore, the actual risk has not yet been 
accurately determined. The WHO recommends avoiding systemic steroid use in patients 
with COVID-19 (not limited to asthmatic patients), except in some situations such as septic 
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shock and acute respiratory distress syndrome.11,24-26 All asthmatic patients should be treated 
with inhaled corticosteroids (ICSs) with/without long-acting beta2-agonists as controllers 
according to the Global Initiative for Asthma (GINA) guidelines.27 It would be better to use a 
metered-dose inhaler or dry-powder inhaler rather than a nebulizer in order to prevent the risk 
of the spread of the virus via the device.28 If patients with mild-to-moderate asthma are well 
controlled and have sufficient maintenance medications, it would be better to postpone face-
to-face visits along with online consultations.29 Considerable efforts should be made to reduce 
the prescribed dose of systemic corticosteroids in order to avoid an immuno-compromised 
status in the management of severe asthma. Elderly patients with asthma or comorbid 
conditions should be more strictly monitored. Additionally, it is recommended that regular 
Ig replacement treatment be maintained in asthmatic patients with IgG subclass deficiency 
suffering from frequent asthma exacerbations.30 Such patients should receive IgG replacement 
treatment during the pandemic, even though they have the risk of exposure to the virus 
during their visits in order to prevent asthma exacerbation.31 Taken together, it is important 
to maintain each patient in an optimal controlled status, and it is not recommended to step-
down controller medications that are maintained.29,32 If patients have asthma exacerbations, 
they should be managed according to the GINA guidelines. When conducting lung function 
tests to monitor control status, the clinical necessity and potential risk of droplet infection 
are compared carefully based on the judgment of the clinician. It is recommended to perform 
spirometry only when its results can draw an immediate treatment descision.33
No specific documents are available for the management of AR during the COVID-19 
pandemic; therefore, stepwise treatment should be performed according to symptom 
severity. However, given the benefits of controlling AR in patients who also have asthma, AR 
should also be treated more actively.34 In cases of mild/intermittent AR or seasonal rhinitis, 
face-to-face consultation should be postponed, and instead non-face-to-face consultation 
(online consultation) is advisable.
From the data available, it is currently clear that children are far less affected by COVID-19 than 
adults and that clinical symptoms are usually milder in children than in adults.35 Moreover, 
according to data from the American CDC, it is found that the prevalence of asthma in children 
(n = 345) with COVID-19 is about 11.5%, which is lower than that in the general population (20%). 
However, these data must be interpreted with caution because the total number of children 
included in the study was relatively small, and there was a considerable amount of missing data.36 
Although specific studies on the effect of COVID-19 in asthmatic children have not been published 
yet, COVID-19 may not be an asthmogenic virus in children. In a review article, it is suggested that 
pediatric allergists should treat patients with asthma, AR or other allergic conditions according to 
the usual guidelines. In addition, there is no evidence that currently available asthma and allergy 
medications, including antihistamines, ICSs and bronchodilators, increase the risk of disease 
exacerbation by COVID-19. It is also not advisable to stop oral steroids in the management of 
asthma if the patient is already taking these medications or to avoid oral steroids for the treatment 
of an acute asthma attack even if it is due to COVID-19.31 Although additional studies are needed 
in patients with pediatric asthma, it seems that COVID-19 is not a risk for asthma exacerbation in 
healthy or asthmatic children. During the current pandemic, asthmatic children should continue 
to receive preventive treatment in order to be under good control. There have been no studies 
on the effect of COVID-19 on AR in children yet. The Allergic Rhinitis and its Impact on Asthma 
(ARIA)-European Academy of Allergology and Clinical Immunology (EAACI) mentioned that 
patients with common allergic conditions do not develop additional distinct symptoms or seem 
to be at increased risk of severe disease when infected with COVID-19.37
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Atopic dermatitis
AD is a chronic inflammatory skin disease characterized by recurrent eczematous skin 
lesions and pruritus. Not only is AD associated with airway diseases such as asthma and 
AR, but patients with severe AD are also likely to be vulnerable to respiratory infections 
because of their systemic immunosuppressive treatment.38 However, discontinuation of 
immunosuppressive agents should not be applied in all AD cases, since it can lead to the 
aggravation of AD and even to disseminated viral skin diseases such as eczema herpeticum.39 
Maintenance of skin hygiene and the use of moisturizers and topical immunosuppressive 
agents would be preferable options in the treatment of AD. However, systemic 
immunosuppressant or immune-modulating agents, such as dupilumab, seem unlikely to 
elevate the risk of COVID-19. A recent Italian study reported that only 2 (0.82%) of 245 AD 
patients treated with dupilumab developed COVID-19, and they successfully recovered from 
COVID-19 while maintaining dupilumab therapy.40 Taken together, to maintain optimal 
skincare, topical immunosuppressant and immune-modulating therapies should not be 
deferred or stopped if needed on the basis of physicians' judgment to prevent flares of AD.
Chronic urticaria (CU) and drug allergy
CU is defined as urticaria that has been present for at least 6 weeks and required long-term 
maintenance therapy because symptoms can last for years in many cases.41 In healthy subjects 
without any underlying diseases, CU symptoms are not usually life-threatening, and visiting 
healthcare facilities needs to be delayed and rescheduled (a few weeks to a few months) 
during the COVID-19 pandemic. To avoid this highly contagious disease, it is necessary 
to reduce unnecessary visits to hospitals and to be isolated at home. In particular, older 
patients with comorbidities, such as hypertension, diabetes, cardiovascular disease and 
chronic respiratory disease, are vulnerable to infections and are more cautious in visiting 
hospitals.42,43 However, visiting healthcare facilities would be of some benefit in patients 
experiencing significant deterioration in the quality of life without regular medication. 
When patients develop severe symptoms, such as anaphylaxis, angioedema, bronchospasm, 
dizziness, and hypotension accompanying urticaria, they should visit the emergency 
department to treat symptoms. Patients are required to follow all the policies for infection 
control. Physicians should delay the evaluation of the causes of CU and reschedule patient 
outpatient visits until the pandemic is over.
Drug allergy can be managed according to similar basic principles. Drug allergy should be 
immediately treated especially in the presence of symptoms, such as generalized urticaria, 
angioedema, bronchospasm and hypotension. Epinephrine injection is contemplated in 
cases of suspected anaphylaxis. Diagnostic procedures, such as drug challenge and drug skin 
tests, are required to be delayed until the pandemic is over. Drug desensitization is actively 
considered in patients who need immediate administration of hypersensitivity drugs. In 
principle, desensitization needs to be performed in the hospital according to the infection 
control procedure.44
BIOLOGIC TREATMENT
Regular administration of biologics, such as anti-IL-5, anti-IL-4 and anti-IgE antibodies, has 
become a common treatment option for severe asthma as well as for uncontrolled cases of 
CU and AD. It is critical to control disease activity through the prevention of exacerbations.45 
In addition, there have been no studies showing that biological agents may induce immune 
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suppression and increase the risk of COVID-19. For these reasons, there is no need to stop or 
reduce the dosage of biologics scheduled.29 However, most of the biologics require periodic 
parenteral/subcutaneous administration, for which such patients have to visit an allergy clinic 
to receive medications according to a treatment protocol. In these patients, it is advisable 
to provide required protective equipment to both HCWs and patients and to administer the 
medication with minimal contact.9,10
In allergic children, biologics are mainly used in patients with severe eczema or severe 
asthma. There have been no studies or guidelines on the usage of biologics in allergic children 
during the COVID-19 pandemic. A case report suggested that immunosuppressive therapy 
with biologics might be effective in COVID-19 patients with an overactive immune response, 
cytokine storm; however, there have been no systematic studies on this.46 When children under 
treatment with biologics are infected with COVID-19 and present with only mild symptoms, 
the treatment can be continued. However, when either adults or children who develop severe 
COVID-19 symptoms, the treatment should be delayed until they completely recover.
CONCLUSION
It is still uncertain whether COVID-19 increases the risk of aggravating asthma or allergic 
diseases. Detailed monitoring and optimal treatment with AIT, ICS and biologics need 
to be continued in all patients suffering from asthma and allergic diseases. This can be 
achieved in a safe condition using optimal protective measures. Patients at high risk (older 
age and comorbid conditions) should be monitored more strictly. We applaud all the allergy/
immunology specialists who strive to stay up for optimal health protection by focusing on 
patient management during the COVID-19 pandemic.
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